Hillhouse, a global Asia-focused private equity firm, agreed to acquire a 15.6% stake in Luye Pharma, an international pharmaceutical company, for $161m. "It's a great honor for us to see that Hillhouse recognizes the value of Luye Pharma, and Hillhouse is also very welcome to become our strategic investor and a major shareholder. We very much appreciate Hillhouse's investment philosophy and its application in practice, which have been successful around the globe for many years. I believe that based on our shared values, the powerful support and collaboration of Hillhouse will provide a tremendous boost to the future growth of Luye Pharma. We will definitely work together to launch many more high-quality new drugs with clinical value, better serve global patients, and create more value for our shareholders," Liu Dianbo, Luye Pharma Executive Chairman of the Board of Directors.